ARTV: Artiva Biotherapeutics, Inc. Price/Earnings to Growth Multiple

Symbol and logo of brand Artiva (ARTV)

Artiva Biotherapeutics, Inc. (ARTV) possesses a unique mass-production technology for NK cells that provides significant pricing power. Success is based on production scalability and clinical data, while Big Pharma support keeps patients within the therapy ecosystem. The peg_co multiple helps assess the asset's value relative to profit growth rates, where 0.00 serves as the base parameter value for analyzing the company's undervaluation.

Price/Earnings to Growth Ratio: Artiva Biotherapeutics Inc. (ARTV) for 07/20/2024 - 11/18/2026

Analytical breakdowns for artivabio.com (ARTV)

Fundamental company analysis:artivabio.com, ARTV
Mass-produced product of Artiva Biotherapeutics, Inc.

The PEG ratio determines investment attractiveness by comparing a stock's market value with its earnings growth. This metric divides the P/E ratio by the annual EPS growth rate, where a value below one signals that the asset is undervalued. Tracking the PEG level allows investors to filter out market noise and identify growth potential. For Artiva Biotherapeutics, Inc. (ARTV), this is critical when scaling accessible NK-therapy. The innovative method for treating autoimmune diseases creates a foundation for earnings expansion.

Who Artiva Biotherapeutics, Inc. competes with

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|Aura Biosciences Inc - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics CADL|accuray.com - PEG Multiple|SLS: Price/Earnings to Growth Ratio|ACTU (actuatetherapeutics.com) - Price/Earnings to Growth Multiple|CTOR - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio tuhurabio.com|PEG Multiple Protara Tx|Price/Earnings to Growth Multiple FATE (Fate Therapeutics Corp)|Price/Earnings to Growth Ratio WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|Champions Oncology (CSBR) - Price to Earnings Adjusted for Growth Rate|XBiotech - PEG Multiple|CEL-SCI (CVM) - Price/Earnings to Growth Multiple|OS Therapies Inc (OSTX) - Price/Earnings to Growth Ratio|radiopharmtheranostics.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple ANL|Price/Earnings to Growth Ratio VERU|PEG Multiple TPST|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple